idarubicin has been researched along with Leukemia, Lymphocytic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Majsterek, I; Pytel, D; Wysocki, T | 1 |
| Annaloro, C; Baldini, L; Lambertenghi-Deliliers, G; Maiolo, AT; Pogliani, E; Polli, E | 1 |
| Bagnulo, S; Canino, R; Carli, M; Colella, R; Comelli, A; De Bernardi, B; Grazia, G; Madon, E; Paolucci, G; Sainati, L | 1 |
| Chesterman, CN; Griffiths, JD; Harris, MG; Herrmann, RP; Lowenthal, RM; Manoharan, A; Rooney, KF; Rozenberg, MC; Salem, HH; Wolf, MM | 1 |
| Fülle, HH; Hellriegel, KP | 1 |
| Carella, AM; Cerri, R; Congiu, A; Damasio, E; Giordano, D; Martinengo, M; Nati, S; Risso, M; Rossi, E; Santini, G | 1 |
6 other study(ies) available for idarubicin and Leukemia, Lymphocytic
| Article | Year |
|---|---|
Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Topics: Antibiotics, Antineoplastic; Apoptosis; Benzamides; Caspase 3; Caspases; Cell Cycle; Cell Proliferation; DNA Damage; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; K562 Cells; Leukemia, Lymphoid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Lymphoid; Leukocyte Count; Male; Middle Aged; Prednisone; Splenomegaly; Vincristine | 1984 |
Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Lymphoid; Male; Remission Induction | 1987 |
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Lymphoid; Male; Middle Aged | 1987 |
Idarubicin in refractory acute leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Parenteral; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
Topics: Acute Disease; Adolescent; Adult; Daunorubicin; Drug Evaluation; Drug Resistance; Female; Humans; Idarubicin; Leukemia; Leukemia, Lymphoid; Male; Middle Aged; Pilot Projects | 1985 |